Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose Ticagrelor vs High-dose Clopidogrel in Clopidogrel-Resistant ACS
NCT03062462Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Feb 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: The platelet aggregation rate at 7 days. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03062462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062462.